279 East Grand Avenue
South San Francisco
Tel: (650) 730-7074
About insitro inc
insitro is a drug discovery and development company using machine learning and data generation at scale to transform the way that drugs are discovered and delivered to patients. We rely on human genetic cohorts, human-derived cellular disease models, and high-throughput biology and chemistry to identify coherent patient segments, actionable therapeutic targets, and new or existing chemical matter. The goal is to deliver predictive insights to improve the probability of success and reduce the number of costly dead ends along the R&D journey. The company has established enabling collaborations with Gilead in NASH and Bristol Myers Squibb in ALS and is building a pipeline of wholly owned and partnered medicines leveraging its unique insights on patient biomarkers, targets, and molecules. insitro is located in South San Francisco, CA and has raised over $600M from top tech, biotech, and crossover investors since formation in 2018. For more information on insitro, please visit the company’s website at www.insitro.com.
16 articles with insitro inc
9/10/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion Collaboration to Advance Targets and Therapeutic Candidates SAN FRANCISCO--( BUSINESS WIRE )-- insitro, a machine-learning driven drug discovery and development compan
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
insitro, a machine-learning driven drug discovery and development company, announced the appointment of Roger Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories, Merck’s global R&D organization, as the company’s first independent board director.
The funding will be used to continue to build the company’s technology and automation, which enable data generation at a larger scale. This will expand Insitro’s ability to create predictive models of human disease.
12/6/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.
Dr. Batzoglou brings to insitro more than two decades of expertise in machine learning and computational genomics as a former Professor of Computer Science at Stanford University and Vice President of Applied and Computational Biology at Illumina.
Matthew Rasmussen, Ph.D., Appointed as Vice President, Data Engineering Duane Valz Appointed as General Counsel
insitro, a machine-learning driven drug discovery and development company, today announced two key leadership appointments.
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Gilead Sciences Inc. and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis.
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.